These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 28680915)
1. Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set. Koch MW; Cutter GR; Giovannoni G; Uitdehaag BMJ; Wolinsky JS; Davis MD; Steinerman JR; Knappertz V Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e358. PubMed ID: 28680915 [TBL] [Abstract][Full Text] [Related]
2. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945 [TBL] [Abstract][Full Text] [Related]
3. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM Mult Scler; 2009 Jun; 15(6):715-20. PubMed ID: 19383646 [TBL] [Abstract][Full Text] [Related]
4. Composite end points to assess delay of disability progression by MS treatments. Zhang J; Waubant E; Cutter G; Wolinsky J; Leppert D Mult Scler; 2014 Oct; 20(11):1494-501. PubMed ID: 24675040 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Koch MW; Mostert J; Uitdehaag B; Cutter G Mult Scler; 2020 Oct; 26(12):1540-1549. PubMed ID: 31517591 [TBL] [Abstract][Full Text] [Related]
7. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237 [TBL] [Abstract][Full Text] [Related]
9. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies. Hernandez L; O'Donnell M; Postma M; Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685 [TBL] [Abstract][Full Text] [Related]
10. Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment. Wasem J; Heer Y; Karamasioti E; Muros-Le Rouzic E; Marcelli G; Di Maio D; Braune S; Kobelt G; Dillon P Pharmacoecon Open; 2024 Jul; ():. PubMed ID: 38949748 [TBL] [Abstract][Full Text] [Related]
11. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389 [TBL] [Abstract][Full Text] [Related]
12. A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Koch MW; Mostert JP; Uitdehaag B; Cutter G Mult Scler; 2021 Oct; 27(12):1864-1874. PubMed ID: 33464149 [TBL] [Abstract][Full Text] [Related]
13. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Kragt JJ; van der Linden FA; Nielsen JM; Uitdehaag BM; Polman CH Mult Scler; 2006 Oct; 12(5):594-8. PubMed ID: 17086905 [TBL] [Abstract][Full Text] [Related]
14. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker. Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633 [TBL] [Abstract][Full Text] [Related]
15. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Bosma L; Kragt JJ; Polman CH; Uitdehaag BM Mult Scler; 2013 Mar; 19(3):326-33. PubMed ID: 22907939 [TBL] [Abstract][Full Text] [Related]
16. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Benkert P; Kuhle J; Friede T; Ludolph AC; Ziemann U; Kümpfel T; Tumani H Ann Clin Transl Neurol; 2024 Feb; 11(2):477-485. PubMed ID: 38111972 [TBL] [Abstract][Full Text] [Related]
17. The timed 25-foot walk in a large cohort of multiple sclerosis patients. Kalinowski A; Cutter G; Bozinov N; Hinman JA; Hittle M; Motl R; Odden M; Nelson LM Mult Scler; 2022 Feb; 28(2):289-299. PubMed ID: 34100297 [TBL] [Abstract][Full Text] [Related]
18. Japanese translation and validation of the 12-item Multiple Sclerosis Walking Scale version 2. Miyazaki Y; Niino M; Takahashi E; Sato C; Naganuma R; Amino I; Akimoto S; Minami N; Kikuchi S Mult Scler Relat Disord; 2024 Sep; 89():105768. PubMed ID: 39003823 [TBL] [Abstract][Full Text] [Related]
19. Correlation of the VEMP score, ambulation and upper extremity function in clinically isolated syndrome. Crnošija L; Krbot Skorić M; Gabelić T; Adamec I; Brinar V; Habek M J Neurol Sci; 2015 Dec; 359(1-2):197-201. PubMed ID: 26671112 [TBL] [Abstract][Full Text] [Related]